Forvis Mazars Wealth Advisors LLC Buys 118 Shares of DexCom, Inc. (NASDAQ:DXCM)

Forvis Mazars Wealth Advisors LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,481 shares of the medical device company’s stock after acquiring an additional 118 shares during the quarter. Forvis Mazars Wealth Advisors LLC’s holdings in DexCom were worth $1,359,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Howard Capital Management Inc. boosted its holdings in shares of DexCom by 3.0% during the fourth quarter. Howard Capital Management Inc. now owns 10,921 shares of the medical device company’s stock worth $849,000 after acquiring an additional 317 shares during the period. TCW Group Inc. lifted its holdings in DexCom by 2.3% during the 4th quarter. TCW Group Inc. now owns 870,096 shares of the medical device company’s stock worth $67,667,000 after purchasing an additional 19,962 shares during the last quarter. Fisher Funds Management LTD bought a new stake in DexCom in the 4th quarter valued at $96,507,000. Bradley Foster & Sargent Inc. CT acquired a new position in DexCom in the 4th quarter valued at $205,000. Finally, Cromwell Holdings LLC increased its position in DexCom by 252.0% during the 4th quarter. Cromwell Holdings LLC now owns 1,320 shares of the medical device company’s stock worth $103,000 after buying an additional 945 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several research reports. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Citigroup raised their target price on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Wells Fargo & Company raised their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Stock Performance

Shares of DexCom stock opened at $88.78 on Monday. The company’s 50 day moving average price is $83.50 and its two-hundred day moving average price is $76.06. The firm has a market capitalization of $34.69 billion, a P/E ratio of 62.08, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.